General
Preferred name
CAFFEINE
Synonyms
CAFFEINE HYDROBROMIDE ()
Caffeine (1,3,7-trimethylxanthine) ()
PMID28870136-Compound-52 ()
Guaranine ()
Caffeine component of medigesic plus ()
Caffeinum ()
Caffeine component of orphengesic ()
Coffeinum ()
Yeast-Vite ()
Vivarin ()
Caffeine component of invagesic ()
Durvitan ()
Caffeine anhydrous ()
NSC-5036 ()
Pro-Plus ()
Caffeine component of synalgos-dc ()
Caffeine component of triad ()
Caffeine melting point standard ()
Zanthine ()
Synalgos ()
Anhydrous caffeine ()
Caffeine component of lanorinal ()
Caffeine component of wigraine ()
Caffeine component of orphengesic forte ()
Caffeine component of fioricet ()
FEMA NO. 2224 ()
Caffeine component of cafergot ()
Caffeine component of esgic ()
Caffeine component of trezix ()
Caffeine component of migergot ()
Caffeine component of dhc plus ()
Caffeine component of excedrin ()
Caffeine component of anoquan ()
Caffeine component of darvon compound ()
Caffeine component of norgesic ()
Caffeine component of synalgos-dc-a ()
Caffeine component of fiorinal ()
Caffeine component of invagesic forte ()
Nodoz ()
Caffeine component of femcet ()
CAFFEINE, CITRATED ()
Citrated caffeine ()
Peyona ()
Peyona (previously nymusa) ()
Caffeine mixture with citric acid ()
Cafcit ()
Gencebok ()
Caffeine citrate ()
Caffeine-d3 ()
Caffeine-d3 (CRM) ()
Caffeine (CRM) ()
Caffeine-13C3 (CRM) ()
P&D ID
PD002448
CAS
58-08-2
5743-18-0
26351-03-1
2406-91-9
69-22-7
114303-55-8
78072-66-9
Tags
available
drug
natural product
Approved by
FDA
First approval
1948
1999
Drug indication
Atrial fibrillation
premature birth
Orthostatic hypotension
Drug Status
investigational
approved
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Caffeine is a central nervous system stimulant that causes increased alertness and agitation. (GtoPdb)
DESCRIPTION Caffeine is a methylxanthine alkaloid naturally found in various plant parts that acts as an antagonist at central adenosine receptors at relevant physiological concentrations. It is used to increase alertness. It is also used in to prevent and treat pulmonary complications of premature birth. (Enamine Bioactive Compounds)
DESCRIPTION Phosphodiesterase inhibitor; central stimulant (LOPAC library)
DESCRIPTION Adenosine receptor antagonist; bronchodilator (Tocris Bioactive Compound Library)
Compound Sets
31
Cayman Chemical Bioactives
14118
22975
27970
18247
27971
27972
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
CHEMBL113
CHEMBL1200569
ChEMBL Drugs
CHEMBL113
CHEMBL1200569
Concise Guide to Pharmacology 2017/18
407
Concise Guide to Pharmacology 2019/20
407
Concise Guide to Pharmacology 2021/22
407
Concise Guide to Pharmacology 2023/24
407
Concise Guide to Pharmacology 2025/26
407
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB00201
DrugBank Approved Drugs
DB00201
DrugCentral
463
DrugCentral Approved Drugs
463
DrugMAP
DMFDERP
DMKBJWP
DrugMAP Approved Drugs
DMKBJWP
DrugMatrix
Enamine Bioactive Compounds
EBC-03517
Enamine BioReference Compounds
Guide to Pharmacology
407
Ki Database
caffeine
Caffeine (1,3,7-trimethylxanthine)
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL113
NCATS Inxight Approved Drugs
3G6A5W338E
Novartis Chemogenetic Library (NIBR MoA Box)
Prestwick Chemical Library
ReFrame library
The Spectrum Collection
Tocris Bioactive Compound Library
2793
ZINC Tool Compounds
ZINC000000001084
External IDs
505
Properties
(calculated by RDKit )
Molecular Weight
194.08
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
0
Rotatable Bonds
0
Ring Count
2
Aromatic Ring Count
2
cLogP
-1.03
TPSA
61.82
Fraction CSP3
0.38
Chiral centers
0.0
Largest ring
6.0
QED
0.54
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Selectivity
Phosphodiesterase
MOA
phosphodiesterase inhibitor
Adenosine Receptor antagonist
Antagonist
Adenosine A2a receptor antagonist
Chitinase antagonist
adenosine receptor antagonist, phosphodiesterase inhibitor
Target
cAMP-specific 3',5'-cyclic phosphodiesterase 4B
Adenosine Receptor
Intermediate conductance calcium-activated potassium channel protein 4
ADORA1, ADORA2A, ADORA2B, ADORA3, ATM, ITPR1, ITPR2, ITPR3, PDE10A, PDE11A, PDE1A, PDE1B, PDE1C, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A, PDE6A, PDE6B, PDE6C, PDE7A, PDE7B, PDE8A, PDE8B, PDE9A, PIK3CA, PIK3CB, PIK3CD, PRKDC, RYR1, RYR2, RYR3
Primary Target
Non-selective Adenosine
Member status
virtual
Indication
fatigue, drowsiness
Therapeutic Class
Antihypertensive Agents
Source data